Description: IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, Germany, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; collagen ELISAs for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, it provides lyophilization services for making disposable medical device components; and custom fermentation and contract manufacturing services. It serves manufacturers of medical devices, quality control labs, low molecular weight heparin manufacturers, and academic research institutions. IBEX Technologies Inc. was incorporated in 1972 and is based in Montreal, Canada. As of April 8, 2024, IBEX Technologies Inc. operates as a subsidiary of BBI Solutions OEM Limited.
Home Page: www.ibex.ca
5485 Rue Pare
Montreal,
QC
H4P 1P7
Canada
Phone:
NA
Officers
| Name | Title |
|---|---|
| Mr. Paul Baehr | President, CEO & Chairman |
| Belinda Franco C.A., CPA | CFO, VP of Finance & Administration and Secretary |
| Mr. Mahendra Kumar Pallapothu | Vice President of Operations |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 9.6 |
| Price-to-Book MRQ: | 2.431 |
| Price-to-Sales TTM: | 2.9415 |
| IPO Date: | |
| Fiscal Year End: | July |
| Full Time Employees: | 0 |